Randomized phase 2a study of TAS5315, a Bruton’s tyrosine kinase inhibitor, for chronic spontaneous urticaria

Allergology International · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles